B007

DRUG4 trials

Sponsors

Shanghai Jiaolian Drug Research and Development Co., Ltd

Conditions

Generalized Myasthenia GravisPemphigusPrimary Membranous Nephropathy

Phase 1

A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy

RecruitingNCT05668403

Shanghai Jiaolian Drug Research and Development Co., LtdPrimary Membranous Nephropathy

Start: 2023-03-02End: 2027-12-30Target: 52Updated: 2026-04-30

Phase 2

A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.

RecruitingNCT06447597

Shanghai Jiaolian Drug Research and Development Co., LtdGeneralized Myasthenia Gravis

Start: 2024-07-01End: 2026-12-30Target: 104Updated: 2026-08-14

A Clinical Study of B007 in the Treatment of Pemphigus.

RecruitingNCT06454357

Shanghai Jiaolian Drug Research and Development Co., LtdPemphigus

Start: 2024-07-12End: 2026-12-31Target: 132Updated: 2026-05-05

A Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy.

RecruitingNCT06470191

Shanghai Jiaolian Drug Research and Development Co., LtdPrimary Membranous Nephropathy

Start: 2024-07-30End: 2026-12-31Target: 216Updated: 2026-05-05